GO2 for Lung Cancer remains at the forefront of leading advocacy efforts to restore funding for the Lung Cancer Research Program. In preparation for today’s Senate Appropriations Committee hearing, “Biomedical Research: Keeping America’s Edge in Innovation,” we submitted written testimony to Chairwoman Susan Collins (R-ME), Ranking Member Patty Murray (D-WA), and other Committee Members.

In our testimony, we conveyed the lung cancer community’s deep concern regarding the 57% cut to the Congressionally Directed Medical Research Programs (CDMRP) enacted through the Full-Year Continuing Appropriations and Other Extensions Act (Public Law 119-4). This reduction has eliminated lung cancer research funding for Fiscal Year 2025. Alongside the Defense Health Research Consortium (DHRC), we urged the Committee to restore CDMRP funding fully, whether through a standalone FY 2025 supplemental appropriations bill or by including such funding in the FY 2026 Defense Appropriations Act.

Our testimony emphasized that, without immediate action, these funding cuts will severely hinder critical research, delay patient care and treatment, and compromise the long-term health and readiness of our Armed Forces and the American public.

Read our full written testimony.